Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gaush MeditechFRA:F7Y -2.80%60 EV-to-EBIT is 6.57 as of Sep. 05, 2026, which is 30% above its 10-year median of 5.04. GuruFocus rates FRA:F7Y with a GF Score™ of 60/100 and a GF Value™ of €1.44. The stock has 3 warning signs investors should review. Among 475 Medical Devices & Instruments companies, Gaush Meditech ranks better than 86.95% on this metric.
The historical rank and industry rank for Gaush Meditech's EV-to-EBIT or its related term are showing as below:
FRA:F7Y'
s EV-to-EBIT Range Over the Past 10 Years
Min: -81.01 Med: 5.04 Max: 15.82
Current: 6.59
During the past 7 years, the highest EV-to-EBIT of Gaush Meditech was 15.82. The lowest was -81.01. And the median was 5.04.
FRA:F7Y's EV-to-EBIT is ranked better than 86.95% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 18.61
vs FRA:F7Y: 6.59
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Gaush Meditech's Enterprise Value for the quarter that ended in Dec. 2025 was €133.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gaush Meditech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €12.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gaush Meditech EV-to-EBIT Related Terms
Gaush Meditech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Gaush Meditech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Gaush Meditech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gaush Meditech EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Gaush Meditech's EV-to-EBIT falls into.
Gaush Meditech's current Enterprise Value is €81.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gaush Meditech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €12.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gaush Meditech (FRA:F7Y) has a EV-to-EBIT of 6.57 as of Sep. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Gaush Meditech and its competitors. This is 30% above median its historical median of 5.04. According to the industry distribution chart, Gaush Meditech ranks #62 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 13.1%.
Is Gaush Meditech's EV-to-EBIT too high?
Gaush Meditech's current EV-to-EBIT of 6.57 is 30% above median its 10-year median of 5.04. The Medical Devices & Instruments industry median EV-to-EBIT is 18.61. Gaush Meditech's value of 6.57 is 64.7% below this industry median. Based on the distribution chart, Gaush Meditech ranks #62 out of 475 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Gaush Meditech has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Gaush Meditech's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gaush Meditech ranks #62 out of 475 companies for EV-to-EBIT. This places Gaush Meditech in the top 13% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.61. Gaush Meditech's value of 6.57 is 64.7% below this benchmark. While the company's 10-year median is 5.04 vs. the industry median of 18.61, Gaush Meditech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.61, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gaush Meditech's current EV-to-EBIT of 6.57 is 64.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Gaush Meditech and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gaush Meditech's current EV-to-EBIT is 6.57, which is 30% above median its own 10-year median of 5.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gaush Meditech stock overvalued right now?
Gaush Meditech (FRA:F7Y) has a current EV-to-EBIT of 6.57. The stock's GF Value™ is €1.44, compared to a current price of €0.49 — trading 66.3% below its estimated fair value. The current EV-to-EBIT is 6.57, which is 30% above median its 10-year median of 5.04 and 64.7% below the Medical Devices & Instruments industry median of 18.61. Gaush Meditech's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Gaush Meditech (FRA:F7Y), the current EV-to-EBIT is 6.57 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gaush Meditech (FRA:F7Y) Overvalued in 2026?
Based on GuruFocus' analysis, Gaush Meditech stock appears to be undervalued.
The current stock price of €0.49 is trading 66.3% below its estimated GF Value™ of €1.44.
Key valuation signals for FRA:F7Y:
EV-to-EBIT: 6.57 (30% above median its 10-year median of 5.04)
GF Value™: €1.44 vs. price of €0.49 (66.3% below fair value)
Industry Position: 64.7% below the Medical Devices & Instruments median (#62 of 475)
No single metric tells the full story. See the FRA:F7Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gaush Meditech Ltd is a provider of a broad spectrum of manufacture and sale ophthalmic medical devices and provision of technical services. The segments of the company include Proprietary products segment that derives maximum revenue, develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; Technical services segment provides warranty services, maintenance services and other related consumables; and Others segment.
60GF Score
Get the complete analysis for FRA:F7Y
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F7Y has been successfully added to your 
